This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): IMC-1C11
Description: IMC-1C11 is a monoclonal antibody that targets an epidermal growth factor receptor (EGFR) family member called KDR (VEGFR2). In so doing, it inhibits vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation, thus inhibiting angiogenesis (new blood supply) by blocking the development of capillaries from pre-existing blood vessels to tumors.
Deal Structure: In November 2008 Eli Lilly completed the acquisition of ImClone Systems.
Additional information available to subscribers only: